Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals received FDA Orphan Drug designation for R289, a treatment for myelodysplastic syndromes (MDS), highlighting its potential as a new therapy for patients with unmet medical needs. R289, a dual inhibitor of IRAK1 and IRAK4, is under study in a Phase 1b trial for lower-risk MDS patients.

Rigel Pharmaceuticals received FDA Orphan Drug designation for R289, a potential treatment for myelodysplastic syndromes (MDS), highlighting its development progress and the unmet medical need for MDS patients. R289, an IRAK1/4 dual inhibitor, is under Phase 1b study, showing promise for lower-risk MDS patients.

Rigel Pharmaceuticals' R289, a dual IRAK1/4 inhibitor, received FDA Orphan Drug designation for treating myelodysplastic syndromes (MDS). This designation supports R289's development, offering incentives like tax credits and market exclusivity. R289, also granted Fast Track status, targets lower-risk MDS patients, aiming to address the unmet medical need in this rare disorder.

Rigel Pharmaceuticals' R289, a dual inhibitor of IRAK1 and IRAK4, received FDA Orphan Drug designation for treating myelodysplastic syndromes (MDS). This designation supports R289's development, offering incentives like tax credits and market exclusivity. R289 is in Phase 1b study for lower-risk MDS patients, showing promise as a new treatment option.

Rigel Pharmaceuticals granted 46,131 stock options to eight non-executive employees under its Inducement Plan, approved by the Compensation Committee, to incentivize employment. The options vest over four years with a one-year cliff. Rigel focuses on therapies for hematologic disorders and cancer.

BNP Paribas Financial Markets increased its Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) stake by 1,199.2% in Q3, owning 21,008 shares worth $340,000. Other hedge funds also adjusted their holdings. Analysts revised price targets, with a consensus target of $36.20 and an average rating of 'Moderate Buy'. Rigel Pharmaceuticals' stock opened at $18.91 on Friday, with a 52-week range of $7.48 to $29.82 and a market cap of $333.10 million.